Australian Institute for Bioengineering and Nanotechnology
Availability:
Available for supervision
Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.
I am an academic and consultant working in global health with a focus on health technology assessment (HTA), health systems and services research, and the use of medicines in populations. I have a particular interest in the use of data and research for evidence-informed decision making and implementation science in the context of low and middle income countries, especially in sub-Saharan Africa. I have worked on international health projects in Indonesia and am currently working on several projects in HTA and medicines use in Ghana and sub-Saharan Africa. I work with an extensive network of clinicians and health professionals to investigate the use of medicines and adverse effects in general practice, cancer, psychiatry, neurology, and internal medicine. I have honorary or visiting appointments at the University of Queensland (UQ, Brisbane, Australia), Imperial College London (UK, International Decision Support Initiative) and Kwame Nkrumah University of Science and Technology (KNUST, Kumasi, Ghana). I have a BSc(Hons) and MPH from UQ and a PhD from Monash University. I have lived or worked in Australia (Brisbane, Melbourne), Canada (Toronto), Indonesia (Yogyakarta), UK (London), and Ghana (Accra, Kumasi). I worked as a consultant in HTA in Australia for many years evaluating submissions to subsidise medicines on the Pharmaceutical Benefits Scheme (PBS). I am an experienced teacher having coordinated courses, lectured, and tutored in undergraduate and postgraduate programs. I was a Foundation Coordinator in the UQ Master of Pharmaceutical Industry Practice (from 2019). I am an advisor on diverse PhD and student research projects.
Dr Malcolm Lim is an experienced Cancer Biologist and His research interest spans cancer biology, biomarker discovery and theranostic nanomedicine.
He received his PhD from the University of Queensland (UQ) in 2022. His research, conducted in the labs of Professors Sunil Lakhani and Kristofer Thurecht, involved evaluating the efficacy of using nanomedicine for precision delivery of chemo- or radiotherapeutics against biomarkers in brain metastases. For this work, he developed a clinically-relevant brain metastasis mouse model. His research was recognised with the UQ Dean’s Award for Outstanding Thesis 2022. (DOIs: 10.1021/acs.molpharmaceut.3c00558, 10.3791/64216)
Currently, Malcolm serves as a Postdoctoral Research Fellow at the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) and the Thurecht’s Lab at UQ-Centre for Advanced Imaging (CAI) in Australian Institute for Bioengineering and Nanotechnology (AIBN), where he will apply his multidisciplinary expertise to explore radiobiology and radiation-induced biological responses and to advance targeted pharmaceuticals for challenging cancers.
Prior to joining AMTAR, Malcolm served as a Postdoctoral Researcher where he investigated the molecular mechanisms underlying Early Breast Cancers at the Molecular Breast Pathology Lab, UQ-Centre for Clinical Research, under the mentorship of Professors Sunil Lakhani and Peter Simpson. Before his academic career, Malcolm had five years of experience as a histologist, which provided him with a broad skillset in the field.
Dr Malcolm’s research is well-documented in numerous publications in biomedical research journals despite his career stage, reflecting his passion to advancing cancer research.
Associate Professor Andy Moore is a Paediatric Oncologist and Director of Research at Children's Health Queensland Hospital & Health Service (CHQ). He is also Director of the Queensland Children's Tumour Bank, a unique resource located on the Queensland Children's Hospital precinct, facilitating local, national and international collaborative research across all childhood cancer types and supporting enrolment of children on clinical trials. A/Prof. Moore's clinical and research interests focus on childhood leukaemia, particularly acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. He also holds a number of leadership and advisory roles, including Deputy Chair of the Australian & New Zealand Childrens Haematology / Oncology Group (ANZCHOG).
Dr Natacha Omer is a paediatic oncologist at the Queensland Children's Hospital in Brisbane. She is specialised in solid tumours, with a spacial interest in paediatric and adolescent sarcomas, cancer immunotherapy and molecular oncology. She is undertaking a PhD in immunology studying natural killer (NK) cell immunotherapy in paediatric sarcomas at the Frazer Institute, University of Queensland, in Dr Fernando Guimaraes lab.
Dr Haolu Wang currently is a Medical Registrar and Basic Physician Trainee with the Royal Australasian College of Physicians - The Prince Charles Hospital and Redcliffe Hospital (Northside) Rotation. He is also an Honorary Research Fellow in the joint liver cancer research program of Frazer Institute, The University of Queensland and Gallipoli Medical Research Foundation. Dr Wang received his Bachelor of Medicine and Master of Surgery qualifications from Shanghai Jiao Tong University School of Medicine. He was awarded his PhD in Clinical Medicine from The University of Queensland. Dr Wang has worked as a Medical Officer at Renji Hospital, Shanghai Jiao Tong University School of Medicine and as a Researcher Officer at Frazer Institute, The University of Queensland.
Dr Wang has authored over 30 publications of clinical and translational research in liver diseases, including Hepatology, Theranostics, Int J Cancer, J Exp Clin Cancer Res and Pharmacol Ther. His standing in this field is reflected by awards from Australian National Health and Medical Research Council, United European Gastroenterology, European Microscopy Congress, The University of Queensland, Frazer Family Foundation and Shanghai Jiao Tong University.
